Global Information
회사소개 | 문의 | 비교리스트

Alchemia Limited : 제품 파이프라인 리뷰

Alchemia Ltd - Product Pipeline Review - 2016

리서치사 Global Markets Direct
발행일 2016년 12월 상품 코드 192449
페이지 정보 영문 32 Pages
가격
US $ 1,500 ₩ 1,823,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,646,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,500 ₩ 5,470,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


Alchemia Limited : 제품 파이프라인 리뷰 Alchemia Ltd - Product Pipeline Review - 2016
발행일 : 2016년 12월 페이지 정보 : 영문 32 Pages

알케미어(Alchemia Limited)의 치료제 개발 파이프라인 현황과 각 개발 단계 비교 분석, 표적·작용기전·투여 경로·분자 종류별 치료제 평가, 최신 기업 뉴스와 발표, 후기 단계 및 중지된 프로젝트에 관한 정보를 전해드립니다.

Alchemia Limited의 기본 정보

Alchemia Limited의 개요

  • 주요 정보
  • 기업 정보

Alchemia Limited : R&D 개요

  • 주요 치료 범위

Alchemia Limited : 파이프라인 리뷰

  • 개발 단계별 파이프라인 제품
  • 단독치료 제품

Alchemia Limited : 파이프라인 제품 상황 개요

  • 최종 단계 파이프라인 제품
    • 3상 제품/병용치료 모달리티
  • 임상시험 단계 파이프라인 제품
    • 2상 제품/병용치료 모달리티
    • 1상 제품/병용치료 모달리티
  • 초기 단계 파이프라인 제품
    • 전임상 단계 제품/병용치료 모달리티
    • Drug Discovery 단계 제품/병용치료 모달리티

Alchemia Limited : 치료제 개요

  • irinotecan hydrochloride
  • doxorubicin
  • fluorouracil
  • Antibiotic Program
  • bevacizumab
  • carboplatin
  • cetuximab
  • fondaparinux sodium
  • gemcitabine
  • methotrexate
  • Small Molecules to Inhibit Focal Adhesion Kinase for Solid Tumors
  • vinorelbine tartrate
  • Small Molecule Targeting Parathyroid Hormone
  • Small Molecule Targeting Gastric Inhibitory Polypeptide
  • Small Molecule Targeting GLP-1 For Diabetes
  • Small Molecule Targeting Nav1.7 For Pain
  • Small Molecule Targeting Opioid Receptor For Pain
  • Small Molecule Targeting VPAC Receptor For COPD
  • VAST Based Drug For Multiple Indications

Alchemia Limited : 파이프라인 분석

  • 표적별
  • 투여 경로별
  • 분자 종류별
  • 작용기전별

Alchemia Limited : 최근의 파이프라인 동향

Alchemia Limited : 개발이 중지된 파이프라인 제품

  • 개발이 중지된 파이프라인 제품 프로파일
    • VAST Based Drug For Obesity
    • ACL-16907

Alchemia Limited : 기업 발표

Alchemia Limited : 본사와 자회사 소재지

부록

LSH 14.07.11

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Summary:

Global Markets Direct's, 'Alchemia Ltd - Product Pipeline Review - 2016', provides an overview of the Alchemia Ltd's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Alchemia Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the pipeline therapeutic landscape of Alchemia Ltd
  • The report provides overview of Alchemia Ltd including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Alchemia Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Alchemia Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy:

  • Evaluate Alchemia Ltd's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Alchemia Ltd
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Alchemia Ltd's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Alchemia Ltd Snapshot
    • Alchemia Ltd Overview
    • Key Facts
  • Alchemia Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Alchemia Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Alchemia Ltd - Pipeline Products Glance
    • Alchemia Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Alchemia Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Alchemia Ltd - Drug Profiles
    • HA-5FU - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HA-Doxorubicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody 2 to Target CD44 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Respiratory, Oncology, Cardiovascular, Metabolic Disorders, Infectious Disease and Neurology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Glycosyltransferase for Gram-Positive Bacterial Infection - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Alchemia Ltd - Pipeline Analysis
    • Alchemia Ltd - Pipeline Products by Target
    • Alchemia Ltd - Pipeline Products by Route of Administration
    • Alchemia Ltd - Pipeline Products by Molecule Type
    • Alchemia Ltd - Pipeline Products by Mechanism of Action
  • Alchemia Ltd - Dormant Projects
  • Alchemia Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ACL-16907
      • VAST Based Drug For Obesity
  • Alchemia Ltd - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Alchemia Ltd, Key Facts
  • Alchemia Ltd - Pipeline by Indication, 2016
  • Alchemia Ltd - Pipeline by Stage of Development, 2016
  • Alchemia Ltd - Monotherapy Products in Pipeline, 2016
  • Alchemia Ltd - Phase II, 2016
  • Alchemia Ltd - Preclinical, 2016
  • Alchemia Ltd - Discovery, 2016
  • Alchemia Ltd - Pipeline by Target, 2016
  • Alchemia Ltd - Pipeline by Route of Administration, 2016
  • Alchemia Ltd - Pipeline by Molecule Type, 2016
  • Alchemia Ltd - Pipeline Products by Mechanism of Action, 2016
  • Alchemia Ltd - Dormant Developmental Projects,2016
  • Alchemia Ltd - Discontinued Pipeline Products, 2016
  • Alchemia Ltd, Subsidiaries

List of Figures

  • Alchemia Ltd - Pipeline by Top 10 Indication, 2016
  • Alchemia Ltd - Pipeline by Stage of Development, 2016
  • Alchemia Ltd - Monotherapy Products in Pipeline, 2016
  • Alchemia Ltd - Pipeline by Target, 2016
  • Alchemia Ltd - Pipeline by Molecule Type, 2016
  • Alchemia Ltd - Pipeline Products by Mechanism of Action, 2016
Back to Top
전화 문의
F A Q